Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Product › Details

Vitrakvi®

Products Next higher product group larotrectinib (LOXO-101)
Period Status 2018-11-26 registration start
Organisation Organisation Loxo Oncology Inc. (Nasdaq: LOXO)
Document Source Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT.
     

   
Record changed: 2019-01-07

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for cancer drug


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top